Recently, MGI's proprietary high-throughput genetic sequencer DNBSEQ-T7*, was officially delivered to GrandOmics. With the support of DNBSEQ-T7*, GrandOmics aims to become a leading provider of long-read and short-read sequencing service, and further consolidate its innovative development in sequencing services and precision medicine.

Long-read and short-read sequencing technologies will jointly promote the innovative development of GrandOmics' business.

GrandOmics has accumulated extensive project experience in sequencing services and precision medicine, and is committed to providing users with fast, stable, and high-quality long-read and long-read sequencing services through continual investment in R&D and technological innovation.

Powered by DNBSEQ-T7 ultra-high-throughput sequencer*, Grandomics aims to leverage short-read and long-read sequencing technology to further promote the innovative business development and high-quality services. Thanks to its flexible sequencing throughput, excellent data quality and stable operational performance, GrandOmics will rapidly expand its product portfolio in sequencing services and precision medicine.

DNBSEQ-T7 Arrivals at Grandomics

MGI aims to empower more users to achieve the ultimate service

"Before the arrival of DNBSEQ-T7, we were already the user of MGISEQ-2000 high-throughput sequencing platform* since 2019. We are pleased to add DNBSEQ-T7 to better promote the innovative applications of genetic sequencing technology in scientific services and precision medicine." Said Depeng Wang, CEO of GrandOmics.

The Ultra-high throughput Sequencing Platform DNBSEQ-T7*

"High-quality sequencing platforms play a fundamental role in the development of life science research and precision medicine. With the high speed, flexible and ultra-high throughput advantages of DNBSEQ-T7*, we hope to empower more downstream users to break through key technological barriers and jointly promote the innovative development in life science and precision medicine with our partners." Said Jianghui, COO of MGI.

About GrandOmics

GrandOmics is an internationally renowned pioneer in third-generation sequencing (TGS). Founded on August 8, 2011, our company was previously known by the brand Nextomics, and is the first company in China providing third-generation sequencing services.

For many years, we have established a sophisticated set of applications for leading TGS platform, featuring four key modules: genome research services, clinical services, bioinformatics, and advanced manufacturing. Nearly 5,000 square meters of research service platforms, medical testing laboratories, and GMP production plants have been constructed in cities such as Beijing, Wuhan, and Suzhou. These facilities are filled with highly advanced platforms such as MGISEQ-2000 and DNBSEQ-T7 high-throughput sequencers*.

*Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium and Italy.